Prostate Specific Antigen Kit ELISA

N° du produit ABIN5526768

Ce kit ELISA Colorimetric est destiné à la mesure quantitative de Humain Prostate Specific Antigen.

Aperçu rapide pour Prostate Specific Antigen Kit ELISA (ABIN5526768)

Antigène: Prostate Specific Antigen (PSA)

Reactivité: Humain

Méthode de détection: Colorimetric

Type de méthode: Sandwich ELISA

Gamme de detection: 0.04-40 ng/mL

Application: ELISA

Type d'échantillon: Plasma, Cell Culture Supernatant, Serum

Détail du produit Prostate Specific Antigen Kit ELISA

Seuil minimal de détection: 0.04 ng/mL

Fonction: This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human PSA.

Analytical Method: Quantitative

Specificité: PSA

Ingrédients: plate, standard, diluent

Matériel non inclus: pipettes, tubes, reader

Information d'application

Volume d'échantillon: 100 μL

Durée du test: 3 - 4 h

Plaque: Pre-coated

Restrictions: For Research Use only

Stockage

Buffer: 0.02 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Détail du antigène

Antigène: Prostate Specific Antigen (PSA)

Autre désignation: KLK3

Sujet: Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene. PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland. PSA is produced for the ejaculate, where it liquefies semen in the seminal coagulum and allows sperm to swim freely. It is also believed to be instrumental in dissolving cervical mucus, allowing the entry of sperm into the uterus. PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders. Obesity has been reported to reduce serum PSA levels. PSA levels can be also increased by prostatitis, irritation and benign prostatic hyperplasia producing a false positive result. PSA is not a unique indicator of prostate cancer, but may also detect prostatitis or benign prostatic hyperplasia. 30 percent of patients with high PSA have prostate cancer diagnosed after biopsy. Clinical practice guidelines for prostate cancer screening vary and are controversial due to uncertainty as to whether the benefits of screening ultimately outweigh the risks of overdiagnosis and over treatment.

NCBI Accession: NM_001030047

UniProt: P07288

Pathways: Système du Complément